elzasonan
Small moleculeexperimental
Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy. By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00275197)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 1 receptors; 5-HT1B & 5-HT1DANTAGONIST
Serotonin 1 receptors; 5-HT1B & 5-HT1D antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(c2ccccc2/C=C2\SCCN(c3ccc(Cl)c(Cl)c3)C2=O)CC1- Mol. weight
- 448.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3185463 ↗
- WikipediaElzasonan ↗
- ChEMBLCHEMBL2110932 ↗
- ChEMBLCHEMBL2106698 ↗
Also known as
- 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)benzylidene)thiomorpholin-3-one
- cp448187
- cp 448187
- cp 448,187
- cp-448187
- cp-448,187
- cp448,187
- cp-448187-01
- cp-448187-01
- elzasonan
- elzasonan
- elzasonan
- elzasonan
- elzasonan hcl
- elzasonan hcl
- elzasonan hydrochloride
- elzasonan hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00275197 | Phase 2 | Dec 1, 2005 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1